Octreotide in Preventing Diarrhea in Patients Who Are Undergoing Radiation Therapy to the Pelvis

This study has been completed.

Study NCT00033605 Information provided by National Cancer Institute (NCI)

First Received: April 9, 2002 Last Updated: February 18, 2011 History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Study Status:	This study has been completed.
Estimated Study Completion Date:	No date given
Primary Completion Date:	July 2006 (Final data collection date for primary outcome measure)

Publications:

Martenson JA, Halyard MY, Sloan JA, Proulx GM, Miller RC, Deming RL, Dick SJ, Johnson HA, Tai TH, Zhu AW, Keit J, Stien KJ, Atherton PJ. Phase III, Double-Blind Study of Depot Octreotide Versus Placebo in the Prevention of Acute Diarrhea in Patients Receiving Pelvic Radiation Therapy: Results of North Central Cancer Treatment Group N00CA. J Clin Oncol. 2008 Sep 2; [Epub ahead of print]

Martenson JA, Sloan JA, Deming RL, et al.: Phase III double-blind study of depot octreotide versus placebo in the prevention of acute diarrhea during pelvic radiation therapy: results of North Central Cancer Treatment Group protocol N00CA. [Abstract] J Clin Oncol 24 (Suppl 18): A-8506, 469s, 2006.